Compare OVBC & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | AVXL |
|---|---|---|
| Founded | 1872 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.5M | 237.2M |
| IPO Year | 1996 | 2013 |
| Metric | OVBC | AVXL |
|---|---|---|
| Price | $42.53 | $2.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 39.0K | ★ 1.4M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.61 | $2.41 |
| 52 Week High | $51.25 | $13.99 |
| Indicator | OVBC | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 49.10 |
| Support Level | $39.62 | $2.62 |
| Resistance Level | $45.64 | $2.80 |
| Average True Range (ATR) | 2.19 | 0.15 |
| MACD | -0.61 | 0.04 |
| Stochastic Oscillator | 11.60 | 63.01 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services in Southeastern Ohio and western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers, and other standard banking products and services.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.